1	Angiotensin	Angiotensin	_	_	_	_	_	_	_
2	II	ii	_	_	_	_	_	_	_
3	activates	activate	_	_	_	_	_	_	_
4	the	the	_	_	_	_	_	_	_
5	proinflammatory	proinflammatory	_	_	_	_	_	_	_
6	transcription	transcription	_	_	_	_	_	_	_
7	factor	factor	_	_	_	_	_	_	_
8	nuclear	nuclear	_	_	_	_	_	_	_
9	factor-kappaB	factor-kappab	_	_	_	_	_	_	_
10	in	in	_	_	_	_	_	_	_
11	human	human	_	_	_	_	_	_	_
12	monocytes	monocyte	_	_	_	_	_	_	_
13	.	.	_	_	_	_	_	_	_

1	The	the	_	_	_	_	_	_	_
2	renin-angiotensin	renin-angiotensin	_	_	_	_	_	_	_
3	system	system	_	_	_	_	_	_	_
4	may	may	_	_	_	_	_	_	_
5	contribute	contribute	_	_	_	_	_	_	_
6	to	to	_	_	_	_	_	_	_
7	the	the	_	_	_	_	_	_	_
8	pathogenesis	pathogenesis	_	_	_	_	_	_	_
9	of	of	_	_	_	_	_	_	_
10	atherosclerosis	atherosclerosis	_	_	_	_	_	_	_
11	.	.	_	_	_	_	_	_	_

1	A	a	_	_	_	_	_	_	_
2	common	common	_	_	_	_	_	_	_
3	feature	feature	_	_	_	_	_	_	_
4	of	of	_	_	_	_	_	_	_
5	all	all	_	_	_	_	_	_	_
6	stages	stage	_	_	_	_	_	_	_
7	of	of	_	_	_	_	_	_	_
8	atherosclerosis	atherosclerosis	_	_	_	_	_	_	_
9	is	be	_	_	_	_	_	_	_
10	inflammation	inflammation	_	_	_	_	_	_	_
11	of	of	_	_	_	_	_	_	_
12	the	the	_	_	_	_	_	_	_
13	vessel	vessel	_	_	_	_	_	_	_
14	wall	wall	_	_	_	_	_	_	_
15	.	.	_	_	_	_	_	_	_

1	The	the	_	_	_	_	_	_	_
2	transcription	transcription	_	_	_	_	_	_	_
3	factor	factor	_	_	_	_	_	_	_
4	nuclear	nuclear	_	_	_	_	_	_	_
5	factor-kappaB	factor-kappaB	_	_	_	_	_	_	_
6	(	(	_	_	_	_	_	_	_
7	NF-kappaB	NF-kappaB	_	_	_	_	_	_	_
8	)	)	_	_	_	_	_	_	_
9	participates	participate	_	_	_	_	_	_	_
10	in	in	_	_	_	_	_	_	_
11	most	most	_	_	_	_	_	_	_
12	signaling	signaling	_	_	_	_	_	_	_
13	pathways	pathway	_	_	_	_	_	_	_
14	involved	involve	_	_	_	_	_	_	_
15	in	in	_	_	_	_	_	_	_
16	inflammation	inflammation	_	_	_	_	_	_	_
17	.	.	_	_	_	_	_	_	_

1	This	this	_	_	_	_	_	_	_
2	study	study	_	_	_	_	_	_	_
3	therefore	therefore	_	_	_	_	_	_	_
4	examined	examine	_	_	_	_	_	_	_
5	the	the	_	_	_	_	_	_	_
6	effect	effect	_	_	_	_	_	_	_
7	of	of	_	_	_	_	_	_	_
8	angiotensin	angiotensin	_	_	_	_	_	_	_
9	(	(	_	_	_	_	_	_	_
10	ANG	ANG	_	_	_	_	_	_	_
11	)	)	_	_	_	_	_	_	_
12	II	ii	_	_	_	_	_	_	_
13	on	on	_	_	_	_	_	_	_
14	NF-kappaB	NF-kappaB	_	_	_	_	_	_	_
15	activation	activation	_	_	_	_	_	_	_
16	in	in	_	_	_	_	_	_	_
17	monocytic	monocytic	_	_	_	_	_	_	_
18	cells	cell	_	_	_	_	_	_	_
19	,	,	_	_	_	_	_	_	_
20	a	a	_	_	_	_	_	_	_
21	major	major	_	_	_	_	_	_	_
22	cellular	cellular	_	_	_	_	_	_	_
23	component	component	_	_	_	_	_	_	_
24	of	of	_	_	_	_	_	_	_
25	human	human	_	_	_	_	_	_	_
26	atheroma	atheroma	_	_	_	_	_	_	_
27	,	,	_	_	_	_	_	_	_
28	by	by	_	_	_	_	_	_	_
29	electrophoretic	electrophoretic	_	_	_	_	_	_	_
30	mobility	mobility	_	_	_	_	_	_	_
31	shift	shift	_	_	_	_	_	_	_
32	assay	assay	_	_	_	_	_	_	_
33	.	.	_	_	_	_	_	_	_

1	ANG	ANG	_	_	_	_	_	_	_
2	II	ii	_	_	_	_	_	_	_
3	,	,	_	_	_	_	_	_	_
4	like	like	_	_	_	_	_	_	_
5	TNFalpha	TNFalpha	_	_	_	_	_	_	_
6	,	,	_	_	_	_	_	_	_
7	caused	cause	_	_	_	_	_	_	_
8	rapid	rapid	_	_	_	_	_	_	_
9	activation	activation	_	_	_	_	_	_	_
10	of	of	_	_	_	_	_	_	_
11	NF-kappaB	NF-kappaB	_	_	_	_	_	_	_
12	in	in	_	_	_	_	_	_	_
13	human	human	_	_	_	_	_	_	_
14	mononuclear	mononuclear	_	_	_	_	_	_	_
15	cells	cell	_	_	_	_	_	_	_
16	isolated	isolate	_	_	_	_	_	_	_
17	from	from	_	_	_	_	_	_	_
18	peripheral	peripheral	_	_	_	_	_	_	_
19	blood	blood	_	_	_	_	_	_	_
20	by	by	_	_	_	_	_	_	_
21	Ficoll	Ficoll	_	_	_	_	_	_	_
22	density	density	_	_	_	_	_	_	_
23	gradient	gradient	_	_	_	_	_	_	_
24	.	.	_	_	_	_	_	_	_

1	This	this	_	_	_	_	_	_	_
2	ANG	ANG	_	_	_	_	_	_	_
3	II	ii	_	_	_	_	_	_	_
4	effect	effect	_	_	_	_	_	_	_
5	was	be	_	_	_	_	_	_	_
6	blocked	block	_	_	_	_	_	_	_
7	by	by	_	_	_	_	_	_	_
8	the	the	_	_	_	_	_	_	_
9	angiotensin	angiotensin	_	_	_	_	_	_	_
10	AT1	at1	_	_	_	_	_	_	_
11	receptor	receptor	_	_	_	_	_	_	_
12	antagonist	antagonist	_	_	_	_	_	_	_
13	losartan	losartan	_	_	_	_	_	_	_
14	.	.	_	_	_	_	_	_	_

1	Specificity	specificity	_	_	_	_	_	_	_
2	of	of	_	_	_	_	_	_	_
3	ANG	ANG	_	_	_	_	_	_	_
4	II-induced	ii-induced	_	_	_	_	_	_	_
5	NF-kappaB	NF-kappaB	_	_	_	_	_	_	_
6	activation	activation	_	_	_	_	_	_	_
7	was	be	_	_	_	_	_	_	_
8	ascertained	ascertain	_	_	_	_	_	_	_
9	by	by	_	_	_	_	_	_	_
10	supershift	supershift	_	_	_	_	_	_	_
11	and	and	_	_	_	_	_	_	_
12	competition	competition	_	_	_	_	_	_	_
13	experiments	experiment	_	_	_	_	_	_	_
14	.	.	_	_	_	_	_	_	_

1	Moreover	moreover	_	_	_	_	_	_	_
2	,	,	_	_	_	_	_	_	_
3	ANG	ANG	_	_	_	_	_	_	_
4	II	ii	_	_	_	_	_	_	_
5	stimulated	stimulate	_	_	_	_	_	_	_
6	NF-kappaB	NF-kappaB	_	_	_	_	_	_	_
7	activation	activation	_	_	_	_	_	_	_
8	in	in	_	_	_	_	_	_	_
9	human	human	_	_	_	_	_	_	_
10	monocytes	monocyte	_	_	_	_	_	_	_
11	,	,	_	_	_	_	_	_	_
12	but	but	_	_	_	_	_	_	_
13	not	not	_	_	_	_	_	_	_
14	in	in	_	_	_	_	_	_	_
15	lymphocytes	lymphocyte	_	_	_	_	_	_	_
16	from	from	_	_	_	_	_	_	_
17	the	the	_	_	_	_	_	_	_
18	same	same	_	_	_	_	_	_	_
19	preparation	preparation	_	_	_	_	_	_	_
20	.	.	_	_	_	_	_	_	_

1	Together	together	_	_	_	_	_	_	_
2	,	,	_	_	_	_	_	_	_
3	the	the	_	_	_	_	_	_	_
4	data	datum	_	_	_	_	_	_	_
5	demonstrate	demonstrate	_	_	_	_	_	_	_
6	the	the	_	_	_	_	_	_	_
7	ability	ability	_	_	_	_	_	_	_
8	of	of	_	_	_	_	_	_	_
9	the	the	_	_	_	_	_	_	_
10	vasoactive	vasoactive	_	_	_	_	_	_	_
11	peptide	peptide	_	_	_	_	_	_	_
12	ANG	ANG	_	_	_	_	_	_	_
13	II	ii	_	_	_	_	_	_	_
14	to	to	_	_	_	_	_	_	_
15	activate	activate	_	_	_	_	_	_	_
16	inflammatory	inflammatory	_	_	_	_	_	_	_
17	pathways	pathway	_	_	_	_	_	_	_
18	in	in	_	_	_	_	_	_	_
19	human	human	_	_	_	_	_	_	_
20	monocytes	monocyte	_	_	_	_	_	_	_
21	.	.	_	_	_	_	_	_	_

1	Copyright	Copyright	_	_	_	_	_	_	_
2	1999	1999	_	_	_	_	_	_	_
3	Academic	Academic	_	_	_	_	_	_	_
4	Press	Press	_	_	_	_	_	_	_
5	.	.	_	_	_	_	_	_	_

